Pre-eminent empowerment and development foundation

Email

eminenteminent@yahoo.com

Phone

T: +2349133330766″

Web

https://pre-eminentempowerment.com.ng/

Address

No 10 , NUT BUILDING, Anguldi Bukuru, Jos, Plateau State 930103
About Pre-eminent empowerment and development foundation

Pre-Eminent Empowerment and Development (PE&D) Foundation was officially registered in July 2024, a milestone that marked the beginning of their mission to improve the health and well-being of communities. As a newly established organisation, they have laid a strong foundation for impactful public health interventions and community engagement. One of their most notable achievements was conducting free Hepatitis B testing for residents of Hawan Kibo community in Riyom Local Government Area of Plateau State. This initiative reached over 3,000 individuals, providing them with information and increasing awareness about Hepatitis B and providing Hepatitis B tests. Their efforts helped them to discover that about 15% of the population had been infected and about 90% had very limited knowledge of its transmission. In addition, the foundation extended its services to provide emergency assistance to accident victims within neighbouring communities. Their team offered immediate medical care, including treating injuries and providing emotional support during critical moments. These interventions reflect their vision and dedication to ensure a society where emerging health crises and auto crash tragedies are minimised, and individuals have access to comprehensive support. Despite limited resources, the PE&D Foundation has continued to build trust and try to foster partnerships to amplify its impact. Moving forward, they aim to expand their outreach, deepen our engagement with community leaders, and secure additional funding to sustain and scale our efforts, especially in providing free Hepatitis B vaccines for communities. They also advocate against discrimination of those who are infected within the state and conduct research on hepatitis B birth dose vaccination among babies within 24hrs of birth.

 

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close